MCID: ALZ008
MIFTS: 18

Alzheimer Disease Risk Factor malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Alzheimer Disease Risk Factor

Aliases & Descriptions for Alzheimer Disease Risk Factor:

Name: Alzheimer Disease Risk Factor 24

Classifications:



Summaries for Alzheimer Disease Risk Factor

MalaCards based summary : Alzheimer Disease Risk Factor is related to spondyloarthropathy 1 and arrhythmogenic right ventricular dysplasia/cardiomyopathy13. An important gene associated with Alzheimer Disease Risk Factor is APOE (Apolipoprotein E). The drugs Progesterone and Estradiol have been mentioned in the context of this disorder. Related phenotypes are Negative genetic interaction between BLM-/- and BLM+/+ and Negative genetic interaction between PTEN-/- and PTEN+/+

Related Diseases for Alzheimer Disease Risk Factor

Symptoms & Phenotypes for Alzheimer Disease Risk Factor

GenomeRNAi Phenotypes related to Alzheimer Disease Risk Factor according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Negative genetic interaction between BLM-/- and BLM+/+ GR00255-A-1 8.96 APOE CR1
2 Negative genetic interaction between PTEN-/- and PTEN+/+ GR00255-A-3 8.62 APOE CR1

Drugs & Therapeutics for Alzheimer Disease Risk Factor

Drugs for Alzheimer Disease Risk Factor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
3
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Pravastatin Approved Phase 4 81093-37-0 54687
6
Simvastatin Approved Phase 4 79902-63-9 54454
7
Haloperidol Approved Phase 4 52-86-8 3559
8
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
9
Citalopram Approved Phase 4 59729-33-8 2771
10
Choline Approved, Nutraceutical Phase 4 62-49-7 305
11
decanoic acid Experimental Phase 4 334-48-5 2969
12 Progestins Phase 4
13
Medroxyprogesterone Phase 4 520-85-4 10631
14 Estradiol valerate Phase 4 979-32-8
15 Contraceptive Agents Phase 4
16 Contraceptive Agents, Male Phase 4
17 Hormone Antagonists Phase 4
18 Hormones Phase 4
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
20 Estradiol 17 beta-cypionate Phase 4
21 Estradiol 3-benzoate Phase 4
22 Estrogens Phase 4
23 Phytoestrogens Phase 4
24 Polyestradiol phosphate Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 Haloperidol decanoate Phase 4
27 Atorvastatin Calcium Phase 4,Phase 2,Phase 3 134523-03-8
28 Cholinergic Agents Phase 4
29 Cholinesterase Inhibitors Phase 4
30 Gastrointestinal Agents Phase 4
31 Neurotransmitter Agents Phase 4,Early Phase 1
32 Nootropic Agents Phase 4
33 Tranquilizing Agents Phase 4,Early Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 1
35 Dopamine Agents Phase 4
36 Dopamine Antagonists Phase 4
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3
38 Hypolipidemic Agents Phase 4,Phase 2,Phase 3
39 Anticholesteremic Agents Phase 4,Phase 2,Phase 3
40 Antiemetics Phase 4
41 Psychotropic Drugs Phase 4,Early Phase 1
42 Lipid Regulating Agents Phase 4,Phase 2,Phase 3
43 Antimetabolites Phase 4,Phase 2,Phase 3
44 Antipsychotic Agents Phase 4
45 Autonomic Agents Phase 4
46 Central Nervous System Depressants Phase 4,Early Phase 1
47
Serotonin Phase 4 50-67-9 5202
48 Serotonin Agents Phase 4
49 Serotonin Uptake Inhibitors Phase 4
50 Neurotransmitter Uptake Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 110)
id Name Status NCT ID Phase
1 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4
2 Do HMG CoA Reductase Inhibitors Affect Abeta Levels? Completed NCT00303277 Phase 4
3 Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke Completed NCT01109836 Phase 4
4 The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia Completed NCT01363648 Phase 4
5 Treatment of Behavioral Symptoms in Alzheimer's Disease Completed NCT00009217 Phase 4
6 Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol Completed NCT01174290 Phase 4
7 Galantamine Augmentation of Escitalopram for Treatment of Depression Terminated NCT00423969 Phase 4
8 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3
9 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Active, not recruiting NCT01760005 Phase 2, Phase 3
10 Metformin in Amnestic Mild Cognitive Impairment Completed NCT00620191 Phase 2
11 Cognitive Effects of Aerobic Exercise for MCI Adults Completed NCT00220467 Phase 2
12 Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment Recruiting NCT02414607 Phase 1, Phase 2
13 A Novel Drug for Borderline Personality Disorder Recruiting NCT02097706 Phase 2
14 Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Recruiting NCT01141023 Phase 2
15 A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease Active, not recruiting NCT00387075 Phase 2
16 Niacin on Immune Activation : a Proof-of-concept Study Active, not recruiting NCT02018965 Phase 2
17 Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment Active, not recruiting NCT01300728 Phase 2
18 Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment Unknown status NCT00149175 Phase 1
19 BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM) Recruiting NCT02502253 Phase 1
20 Psychopathological Risk Factors Associated With Conversion From Mild Cognitive Impairment to Dementia Unknown status NCT01436552
21 The PACO Study ("Personnalité Alzheimer COmportement") Unknown status NCT01297140
22 Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia Unknown status NCT01002586
23 Wii-fit for Activity, Balance and Gait in Assisted Living Unknown status NCT01000038
24 The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's, Vascular and Other Dementias Unknown status NCT01800214
25 Cognitive Effects of Bariatric Surgery Unknown status NCT00671775
26 Amyloid Accumulation After Mild Traumatic Brain Injury Unknown status NCT02134041
27 Posterior Cingulate Function in Persons With Risk Factors for Alzheimer's Disease Completed NCT00478166
28 Gene-Environment Interactions in Alzheimer's Disease Completed NCT00018473
29 Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II Completed NCT00059410
30 MIRAGE: Multi-Institutional Research in Alzheimer's Genetic Epidemiology Completed NCT00239759
31 Predicting the Conversion From Mild Cognitive Impairment to Dementia Completed NCT01823666
32 fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease Completed NCT00478491
33 Early Markers of Cognitive Change and Alzheimer s Disease Completed NCT01867346
34 ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE Completed NCT01772095
35 Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study Completed NCT01729598 Early Phase 1
36 Coordinating Center for Caregiver Intervention Trial Completed NCT00177489
37 Passport to Brain Wellness in Sedentary Adults Completed NCT00979446
38 MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint Completed NCT02825732
39 Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids Completed NCT00850928
40 Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition Completed NCT01286389
41 Genetic Study of Severe Zinc Deficiencies Completed NCT02870166
42 Blood-brain Barrier Quantification in Cerebral Small Vessel Disease Completed NCT02033291
43 Analysis of Visual Pathways in Glaucoma Patients Using a 3tesla-MRI Completed NCT01621841
44 EXCEL: Exercise for Cognition and Everyday Living for Seniors With Memory Complaints Completed NCT00958867
45 Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline Completed NCT00099567
46 Research on Aging Project in Iceland: Second Stage Completed NCT01322568
47 Computational Tools for Early Diagnosis of Memory Disorders Completed NCT02050464
48 Effects of Food Cooking on Diabetes-2 Risk Factors Completed NCT01617304
49 Transcutaneous Bilirubinometers in the Community Completed NCT00735319
50 Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease Completed NCT00544856

Search NIH Clinical Center for Alzheimer Disease Risk Factor

Genetic Tests for Alzheimer Disease Risk Factor

Genetic tests related to Alzheimer Disease Risk Factor:

id Genetic test Affiliating Genes
1 Alzheimer Disease Risk Factor (apoe Genotype) 24 APOE

Anatomical Context for Alzheimer Disease Risk Factor

Publications for Alzheimer Disease Risk Factor

Variations for Alzheimer Disease Risk Factor

Expression for Alzheimer Disease Risk Factor

Search GEO for disease gene expression data for Alzheimer Disease Risk Factor.

Pathways for Alzheimer Disease Risk Factor

GO Terms for Alzheimer Disease Risk Factor

Sources for Alzheimer Disease Risk Factor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....